SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation (Amendment)

9/12/22 2:07:45 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ADPT alert in real time by email

SC 13G/A 1 adpt13gaaug22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ADAPTIVE BIOTECHNOLOGIES (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00650F109 (CUSIP NUMBER) August 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 932,148 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,081,518 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,081,518 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.9% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. 1. Name of Reporting Person T. ROWE PRICE NEW HORIZONS FUND, INC. 52-0791372 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,849,399 6. Shared Voting Power* 0 7. Sole Dispositive Power* 0 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,849,399 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 1.2% 12. Type of Reporting Person IV *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: ADAPTIVE BIOTECHNOLOGIES Item 1(b) Address of Issuer's Principal Executive Offices: 1165 EASTLAKE AVE E, SEATTLE, WASHINGTON 98109 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) (2) T. ROWE PRICE NEW HORIZONS FUND, INC. X Attached as Exhibit A is a copy of an agreement between the Persons Filing (as specified hereinabove) that this Schedule 13G is being filed on behalf of each of them. Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland (2) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 00650F109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 X Investment Company registered under Section 8 of the Investment Company Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: September 12, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President T. ROWE PRICE NEW HORIZONS FUND, INC. Date: September 12, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 08/31/2022 EXHIBIT A AGREEMENT JOINT FILING OF SCHEDULE 13G Price Associates, Inc. (an investment adviser registered under the Investment Advisers Act of 1940), and T. ROWE PRICE NEW HORIZONS FUND, INC., all of which are Maryland corporations, hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934. It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate. It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto. T. ROWE PRICE ASSOCIATES, INC. Date: September 12, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President T. ROWE PRICE NEW HORIZONS FUND, INC. Date: September 12, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President

Get the next $ADPT alert in real time by email

Recent Analyst Ratings for

$ADPT

Date	Price Target	Rating	Analyst
7/5/2023	$15.00	Overweight	JP Morgan
1/5/2023	$15.00	Sector Outperform	Scotiabank
12/21/2022	$7.50 → $14.00	Neutral → Overweight	Piper Sandler
8/25/2022	$8.00	Underperform	Credit Suisse
6/3/2022	$7.50	Neutral	Piper Sandler
2/16/2022	$40.00 → $32.00	Buy	BofA Securities
2/16/2022	$75.00 → $50.00	Overweight	JP Morgan
2/16/2022	$54.00 → $21.00	Neutral	Goldman

More analyst ratings

SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $ADPT

$ADPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer, MRD Bobulsky Susan exercised 5,000 shares at a strike of $1.98, increasing direct ownership by 2% to 253,290 units (SEC Form 4)

SVP and General Counsel Taylor Stacy L sold $121,079 worth of shares (26,922 units at $4.50), decreasing direct ownership by 16% to 139,365 units (SEC Form 4)

Piskel Kyle was granted 31,260 shares, increasing direct ownership by 25% to 154,578 units (SEC Form 4)

$ADPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

Adaptive Biotechnologies upgraded by Piper Sandler with a new price target

$ADPT Press Releases

Fastest customizable press release news feed in the world

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

$ADPT Market Insights

Live Market Insights

Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor

Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting

Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate

$ADPT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

$ADPT Leadership Updates

Live Leadership Updates

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

$ADPT Financials

Live finance-specific insights

$ADPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ADPT SEC Filings

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

Recent Analyst Ratings for
$ADPT

$ADPT
Insider Trading

$ADPT
Analyst Ratings

$ADPT
Press Releases

$ADPT
Market Insights

$ADPT
FDA approvals

$ADPT
Leadership Updates

$ADPT
Financials

$ADPT
Large Ownership Changes

$ADPT
SEC Filings